4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) saw a significant growth in short interest in the month of December. As of December 31st, there was short interest totaling 8,677,770 shares, a growth of 72.7% from the December 15th total of 5,023,933 shares. Approximately 16.8% of the shares of the company are sold short. Based on an average daily volume of 1,473,096 shares, the days-to-cover ratio is currently 5.9 days. Based on an average daily volume of 1,473,096 shares, the days-to-cover ratio is currently 5.9 days. Approximately 16.8% of the shares of the company are sold short.

Insider Transactions at 4D Molecular Therapeutics

In other 4D Molecular Therapeutics news, insider Scott Bizily sold 2,678 shares of the firm’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $12.00, for a total transaction of $32,136.00. Following the completion of the sale, the insider directly owned 3,594 shares in the company, valued at $43,128. This trade represents a 42.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders have sold 6,337 shares of company stock worth $70,649 in the last three months. Company insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of FDMT. BVF Inc. IL grew its holdings in 4D Molecular Therapeutics by 1.5% during the 2nd quarter. BVF Inc. IL now owns 4,629,289 shares of the company’s stock worth $17,175,000 after acquiring an additional 68,000 shares during the period. Federated Hermes Inc. grew its stake in 4D Molecular Therapeutics by 33.4% during the second quarter. Federated Hermes Inc. now owns 1,667,338 shares of the company’s stock worth $6,186,000 after purchasing an additional 417,157 shares during the period. Millennium Management LLC increased its holdings in 4D Molecular Therapeutics by 15.0% in the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after purchasing an additional 213,264 shares in the last quarter. Armistice Capital LLC lifted its stake in 4D Molecular Therapeutics by 265.3% in the third quarter. Armistice Capital LLC now owns 1,096,000 shares of the company’s stock valued at $9,524,000 after buying an additional 796,000 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in shares of 4D Molecular Therapeutics by 2.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 663,657 shares of the company’s stock worth $5,767,000 after buying an additional 14,832 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

FDMT has been the topic of a number of recent research reports. Barclays lowered their target price on 4D Molecular Therapeutics from $38.00 to $33.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 11th. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, October 8th. Chardan Capital reaffirmed a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research report on Thursday, December 18th. Finally, Morgan Stanley raised shares of 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a report on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $33.25.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock traded down $0.88 on Thursday, hitting $7.89. The company had a trading volume of 409,510 shares, compared to its average volume of 811,539. The stock’s 50-day moving average is $9.58 and its two-hundred day moving average is $7.98. The firm has a market cap of $450.51 million, a P/E ratio of -2.11 and a beta of 2.99. 4D Molecular Therapeutics has a twelve month low of $2.23 and a twelve month high of $12.34.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.01. The business had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.40 million. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. Equities research analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.